{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:49:13Z","timestamp":1782211753307,"version":"3.54.5"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"DOI":"10.1515\/jtim-2015-0015","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T05:22:28Z","timestamp":1480915348000},"page":"85-88","source":"Crossref","is-referenced-by-count":0,"title":["Current status and inspiration on macrolides in the treatment of chronic obstructive pulmonary disease"],"prefix":"10.1515","volume":"3","author":[{"given":"Shi-lin","family":"Qiu","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, First Affiliated Hospital of Guangxi Medical University , Nanning , Guangxi Zhuang Autonomous Region , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-ning","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, First Affiliated Hospital of Guangxi Medical University , Nanning , Guangxi Zhuang Autonomous Region , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2015,9,30]]},"reference":[{"key":"2026062310095810529_j_--_ref_001","doi-asserted-by":"crossref","unstructured":"Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23: 590-15.","DOI":"10.1128\/CMR.00078-09"},{"key":"2026062310095810529_j_--_ref_002","doi-asserted-by":"crossref","unstructured":"Mikura S, Wada H, Higaki M, Yasutake T, Ishii H, Kamiya S, et al. Erythromycin prevents the pulmonary inflammation induced by exposure to cigarette smoke. Transl Res 2011; 158: 30-7.","DOI":"10.1016\/j.trsl.2011.03.001"},{"key":"2026062310095810529_j_--_ref_003","doi-asserted-by":"crossref","unstructured":"Zhou Y, Tan X, Kuang W, Liu L, Wan L. Erythromycin ameliorates cigarette smoke-induced emphysema and inflammation in rats. Transl Res 2012 ; 159: 464-72.","DOI":"10.1016\/j.trsl.2011.09.007"},{"key":"2026062310095810529_j_--_ref_004","doi-asserted-by":"crossref","unstructured":"Bai J, Qiu SL, Zhong XN, Huang QP, He ZY, Zhang JQ, et al. Erythromycin enhances CD4+Foxp3+ regulatory T-cell responses in a rat model of smoke-induced lung inflammation. Mediators Inflamm 2012; 2012: 410232.","DOI":"10.1155\/2012\/410232"},{"key":"2026062310095810529_j_--_ref_005","doi-asserted-by":"crossref","unstructured":"He Z, Li B, Yu L, Liu Q, Zhong N, Ran P. Suppression of oxidantinduced glutathione synthesis by erythromycin in human bronchial epithelial cells. Respiration 2008; 75: 202-9.","DOI":"10.1159\/000111569"},{"key":"2026062310095810529_j_--_ref_006","unstructured":"Zhong XN, Guo SM. An experimental study on pulmonary vascular inflammation in a rat model of chronic bronchitis and emphysema. Chin J Tuberc Respir Dis 2006; 29: 435-9."},{"key":"2026062310095810529_j_--_ref_007","doi-asserted-by":"crossref","unstructured":"Duan MC, Tang HJ, Zhong XN, Huang Y. Persistence of Th17\/Tc17 cell expression upon smoking cessation in mice with cigarette smokeinduced emphysema. Clin Dev Immunol 2013; 2013: 350727.","DOI":"10.1155\/2013\/350727"},{"key":"2026062310095810529_j_--_ref_008","doi-asserted-by":"crossref","unstructured":"Yin C, Wang LM, Meng XY. Clinical observation of low dose theophylline combined with inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease. Med J Chin PLA 2007; 32: 777.","DOI":"10.1016\/S8756-3452(08)70341-4"},{"key":"2026062310095810529_j_--_ref_009","doi-asserted-by":"crossref","unstructured":"Li M, Zhong X, He Z, Wen M, Li J, Peng X, et al. Effect of erythromycin on cigarette-induced histone deacetylase protein expression and nuclear factor-kappaB activity in human macrophages in vitro. Int Immunopharmacol 2012; 12: 643-50.","DOI":"10.1016\/j.intimp.2011.12.022"},{"key":"2026062310095810529_j_--_ref_010","doi-asserted-by":"crossref","unstructured":"Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-47.","DOI":"10.1164\/rccm.200801-145OC"},{"key":"2026062310095810529_j_--_ref_011","doi-asserted-by":"crossref","unstructured":"He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 2010; 80: 445-52.","DOI":"10.1159\/000321374"},{"key":"2026062310095810529_j_--_ref_012","doi-asserted-by":"crossref","unstructured":"Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-98.","DOI":"10.1056\/NEJMoa1104623"},{"key":"2026062310095810529_j_--_ref_013","doi-asserted-by":"crossref","unstructured":"Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van\u2019t Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease(COLUMBUS): a randomised, doubleblind, placebo-controlled trial. Lancet Respir Med 2014; 2: 361-8.","DOI":"10.1016\/S2213-2600(14)70019-0"},{"key":"2026062310095810529_j_--_ref_014","doi-asserted-by":"crossref","unstructured":"Yao GY, Ma YL, Zhang MQ, Gao ZC. Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysis. Respiration 2013; 86: 254-60.","DOI":"10.1159\/000350828"},{"key":"2026062310095810529_j_--_ref_015","doi-asserted-by":"crossref","unstructured":"Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 2014; 189: 1503-8.","DOI":"10.1164\/rccm.201402-0207OC"},{"key":"2026062310095810529_j_--_ref_016","doi-asserted-by":"crossref","unstructured":"Simpson JL, Powell H, Baines KJ, Milne D, Coxson HO, Hansbro P. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS One 2014; 9: e105609.","DOI":"10.1371\/journal.pone.0105609"},{"key":"2026062310095810529_j_--_ref_017","doi-asserted-by":"crossref","unstructured":"Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309: 1251-9.","DOI":"10.1001\/jama.2013.1937"},{"key":"2026062310095810529_j_--_ref_018","doi-asserted-by":"crossref","unstructured":"Serisier DJ, Martin ML, McGuckin MA, Lourie R,Chen AC,Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; 309: 1260-7.","DOI":"10.1001\/jama.2013.2290"},{"key":"2026062310095810529_j_--_ref_019","doi-asserted-by":"crossref","unstructured":"Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366: 1881-90.","DOI":"10.1056\/NEJMoa1003833"},{"key":"2026062310095810529_j_--_ref_020","doi-asserted-by":"crossref","unstructured":"Svanstr\u00f6m HH, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368: 1704-12.","DOI":"10.1056\/NEJMoa1300799"},{"key":"2026062310095810529_j_--_ref_021","doi-asserted-by":"crossref","unstructured":"Mortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014; 311: 2199-208.","DOI":"10.1001\/jama.2014.4304"},{"key":"2026062310095810529_j_--_ref_022","doi-asserted-by":"crossref","unstructured":"Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013; 1: 262-74.","DOI":"10.1016\/S2213-2600(13)70038-9"},{"key":"2026062310095810529_j_--_ref_023","doi-asserted-by":"crossref","unstructured":"Li YJ, Shimizu T, Hirata Y, Inagaki H, Takizawa H, Azuma A, et al. EM, EM703 inhibit NF-kB activation-induced by oxidative stress from diesel exhaust particle in human bronchial epithelial cells: importance in IL-8 transcription. Pulm Pharmacol Ther 2013; 26:318-24.","DOI":"10.1016\/j.pupt.2012.12.010"},{"key":"2026062310095810529_j_--_ref_024","doi-asserted-by":"crossref","unstructured":"Mencarelli A, Distrutti E, Renga B, Cipriani S, Palladino G, Booth C, et al. Development of nonantibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis. Eur J Pharmacol 2011; 665:29-39.","DOI":"10.1016\/j.ejphar.2011.04.036"},{"key":"2026062310095810529_j_--_ref_025","doi-asserted-by":"crossref","unstructured":"Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C, Barnes PJ, et al. A novel macrolide\/ fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol 2013; 169: 1024-34.","DOI":"10.1111\/bph.12187"},{"key":"2026062310095810529_j_--_ref_026","doi-asserted-by":"crossref","unstructured":"Kobayashi Y, Wada H, Rossios C, Takagi D, Higaki M, Mikura S, et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kappaB inhibition. J Pharmacol Exp Ther 2013;345:76-84.","DOI":"10.1124\/jpet.112.200733"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/jtim\/3\/3\/article-p85.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2015-0015\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2015-0015\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:20:55Z","timestamp":1782210055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2015-0015\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,1]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,9,30]]},"published-print":{"date-parts":[[2015,9,1]]}},"alternative-id":["10.1515\/jtim-2015-0015"],"URL":"https:\/\/doi.org\/10.1515\/jtim-2015-0015","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,1]]}}}